图书馆订阅: Guest
Begell Digital Portal Begell 数字图书馆 电子图书 期刊 参考文献及会议录 研究收集
真核基因表达评论综述™
影响因子: 1.841 5年影响因子: 1.927 SJR: 0.649 SNIP: 0.516 CiteScore™: 1.96

ISSN 打印: 1045-4403
ISSN 在线: 2162-6502

真核基因表达评论综述™

DOI: 10.1615/CritRevEukarGeneExpr.v5.i3-4.70
pages 365-383

Indirect and Direct Disruption of Transcriptional Regulation in Cancer: E2F and AML-1

Shari Meyers
Department of Tumor Cell Biology, St. Jude Children's Research Hospital, 332 N. Lauderdale, Memphis, TN 38105
Scott W. Hiebert
Department of Tumor Cell Biology, St. Jude Children's Research Hospital, 332 N. Lauderdale, Memphis, TN 38105

ABSTRACT

The disruption of transcriptional regulatory circuits through the elimination of negative regulatory factors (tumor suppressors), the activation of positive acting factors (oncogenes), or when chimeric proteins result from chromosomal translocations, is likely a key event in multistep tumorigenesis. Here, using the transcription factors E2F and AML-1 as model systems, we discuss the disruption of coordinate transcriptional regulation in oncogenesis. E2F oncogenic signals are released when the pRb tumor suppressor is inactivated, and E2F activation may necessitate the coordinate inactivation of a second tumor suppressor, p53. AML-1 is the target of the (8;21) translocation, found in approximately 15% of acute myeloid leukemia (AML) cases, and the t(12;21), found in up to 30% of childhood B-cell acute lymphoblastic leukemias. The t(8;21) creates a fusion protein between AML-1 and a gene of unknown function, mtg8 (ETO), whereas the t(12:21) fuses the TEL (translocation-ets-leukemia) transcription factor to the N-terminus of AML-1. The inv(16), which is the most frequent anomaly found in AML, also targets AML-1, by fusing the gene that encodes AML-l's heterodimeric partner CBFβ to the smooth muscle myosin heavy chain gene MYH11. Thus, E2F and AML-1 provide excellent models for the disruption of transcriptional regulation in cancer.


Articles with similar content:

Cross-Regulation Between WNT and NF-κB Signaling Pathways
Forum on Immunopathological Diseases and Therapeutics, Vol.1, 2010, issue 3
Qiang Du, David Geller
Roles of Smad3 in TGF-β Signaling During Carcinogenesis
Critical Reviews™ in Eukaryotic Gene Expression, Vol.17, 2007, issue 4
Caroline Millet, Ying E. Zhang
Myb-lnduced Transformation
Critical Reviews™ in Oncogenesis, Vol.7, 1996, issue 3-4
Linda Wolff
Mechanisms of Transformation by MLL
Critical Reviews™ in Eukaryotic Gene Expression, Vol.14, 2004, issue 4
Jay L. Hess
Oncogene-lnitiated Aberrant Signaling Engenders the Metastatic Phenotype: Synergistic Transcription Factor Interactions are Targets for Cancer Therapy
Critical Reviews™ in Oncogenesis, Vol.7, 1996, issue 3-4
David T. Denhardt